Revumenib and Sertraline: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Sertraline
No brand names on recordRevumenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's rhythm. Sertraline (an antidepressant) and revumenib (a cancer medicine) can each slightly lengthen a part of your heartbeat called the QT interval. When they are taken together, that effect can add up, which in rare cases can lead to an irregular heartbeat.
The good news is that this is very manageable. Your care team can check your heart with an ECG and keep an eye on things like your potassium and magnesium levels. Please keep taking both medicines as prescribed, and let your doctor or pharmacist know if you feel dizzy, faint, or notice a fluttering heartbeat.
Interaction: Additive QTc prolongation from concurrent sertraline and revumenib. Both agents independently prolong the QT interval, giving a pharmacodynamic (additive) interaction. Neither is a prodrug; effect direction is additive PD, not PK-driven.
- Severity: Major; evidence: theoretical; onset: unspecified.
- Management per labeling: Avoid concomitant use where feasible. Correct electrolyte abnormalities (K+, Mg2+) before starting revumenib.
- Monitoring: ECG at least weekly for first 4 weeks, then at least monthly.
- Interrupt revumenib if QTcF >480 to 60 msec above baseline, restart at lower dose. Discontinue permanently for ventricular arrhythmias or symptomatic prolongation.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
Do not combine revumenib with medications recognized to extend the QTc interval, since this can heighten the likelihood of QT interval prolongation. Any electrolyte abnormalities should be corrected before revumenib is started. Obtain an ECG no less than once weekly during the initial 4 weeks of therapy, and at minimum once a month afterward. Should QTcF rise above 480 msec but stay under 500 msec, hold revumenib, and resume it at the same twice daily dose once the QTcF interval falls back to 480 msec or lower. If QTcF climbs above 500 msec, or increases by more than 60 msec relative to baseline, interrupt revumenib and reintroduce it twice daily at the reduced dose level after the QTcF interval returns to 480 msec or below. Revumenib must be stopped permanently in patients who experience ventricular arrhythmias as well as in those in whom QTc interval prolongation occurs alongside signs or symptoms of a life threatening arrhythmia1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
This interaction is manageable with monitoring. Your care team may take these steps:
- Where possible, they may consider whether an antidepressant with less QT effect is a better fit, so mention all your medicines.
- They will typically check and correct electrolytes (like potassium and magnesium) before starting revumenib.
- They will monitor your heart with an ECG, often weekly for the first 4 weeks and then at least monthly.
- Your revumenib dose may be paused and individualized based on your ECG results.
What you should do: Keep taking both exactly as prescribed, do not stop on your own, and tell your pharmacist or doctor right away about any dizziness, fainting, or palpitations.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) During the clinical trials, prolongation of the QTc interval was documented as an adverse reaction in 39 (29%) of the 135 patients who received revumenib at the recommended dose for relapsed or refractory acute leukemia with a KMT2A translocation; this QTc interval prolongation reached Grade 3 in 12%. The heart-rate corrected QT interval calculated by Fridericia's method (QTcF) exceeded 500 msec in 8%, and the rise from baseline QTcF was greater than 60 msec in 18%. A revumenib dose reduction was necessary in 5% because of QTc interval prolongation. QTc prolongation was seen in 16% of the 31 patients under 17 years of age, 33% of the 88 patients from 17 years to less than 65 years of age, and in 50% of the 16 patients aged 65 years or older 1.
Common questions
Can I take Revumenib and Sertraline together?
Sertraline and revumenib can each prolong the QT interval, so together the risk of an abnormal heart rhythm adds up. Keep taking both as prescribed and expect regular ECG and electrolyte checks from your care team. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Revumenib and Sertraline interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Revumenib and Sertraline interaction managed?
This interaction is manageable with monitoring. Your care team may take these steps: Where possible, they may consider whether an antidepressant with less QT effect is a better fit, so mention all your medicines. They will typically check and correct electrolytes (like potassium and magnesium) before starting revumenib. They will monitor your heart with an ECG, often weekly for the first 4 weeks a… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Revumenib or Sertraline need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: REVUFORJ oral tablets, revumenib oral tablets. Syndax Pharmaceuticals, Inc. (per FDA), Waltham, MA, 2024. DailyMed
Keep reading about Sertraline
Keep reading about Revumenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist